Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 241 | 238 | 0 |
| Samples | 127 | 125 | 0 |
| Peptides | 15 | 12 | 0 |
Function
IGLV5-45 · Immunoglobulin lambda variable 5-45
Predicted to be involved in immune response. Predicted to be located in plasma membrane. Predicted to be part of immunoglobulin complex. Predicted to be active in extracellular space. [provided by Alliance of Genome Resources, Apr 2022]
Isoforms & Proteins
1 transcript · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000390296 | A0A087WSX0 | 241 | 15 |
Gene Properties
Recurrent Mutations
All 15 amino-acid changes on canonical ENST00000390296 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in IGLV5-45 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in IGLV5-45 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Cell Non-Hodgkins Lymphoma | 4/26 15% | 0/0 0% |
| Oral Cavity Carcinoma | 3/54 6% | 0/0 0% |
| T-Lymphoblastic Leukemia | 1/40 2% | 0/0 0% |
| Rhabdomyosarcoma | 3/33 9% | 0/171 0% |
| Acute Myeloid Leukemia | 1/90 1% | 0/0 0% |
| Glioblastoma | 1/98 1% | 0/0 0% |
| Mesothelioma | 2/62 3% | 0/165 0% |
| Adrenocortical Carcinoma | 1/3 33% | 0/112 0% |
| Non-Small Cell Lung Carcinoma | 11/304 4% | 1/1390 0% |
| Biliary Tract Carcinoma | 7/54 13% | 0/950 0% |
| Melanoma | 13/210 6% | 0/1899 0% |
| Plasma Cell Myeloma | 2/44 5% | 0/305 0% |
| Other Solid Cancers | 9/94 10% | 0/1515 0% |
| Neuroendocrine Tumour | 4/154 3% | 0/577 0% |
| Germ Cell Tumour | 1/25 4% | 0/169 0% |
| Endometrial Carcinoma | 2/42 5% | 1/612 0% |
| Cervical Carcinoma | 2/35 6% | 0/422 0% |
| Meningioma | 1/3 33% | 0/252 0% |
| Ewings Sarcoma | 1/63 2% | 0/262 0% |
| Neuroblastoma | 4/87 5% | 0/1331 0% |
| Colorectal Carcinoma | 9/143 6% | 0/3239 0% |
| Other Sarcomas | 2/69 3% | 0/699 0% |
| Pancreatic Carcinoma | 4/89 4% | 0/1611 0% |
| Thyroid Gland Carcinoma | 4/45 9% | 0/1592 0% |
| Glioma | 5/52 10% | 0/2127 0% |
| Squamous Cell Lung Carcinoma | 2/57 4% | 0/810 0% |
| Non-Cancerous | 2/104 2% | 0/830 0% |
| Wilms Tumour | 1/5 20% | 0/474 0% |
| Bladder Carcinoma | 2/58 3% | 0/956 0% |
| Ovarian Carcinoma | 2/109 2% | 0/998 0% |
Mutation Distribution
Where IGLV5-45 is mutated · all tissues, split by cell line vs tissue
How many mutations in IGLV5-45 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 24 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 241 mutations in IGLV5-45
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|